Fmoc-Cl |
| Catalog No.GA10139 |
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 28920-43-6
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
IC50: A series of Fmoc-based dipeptides were reported to show cytotoxicity in human cancer cell lines with the IC50 ranges from 0.4 to 1.0 M.
Fmoc-Cl, a chloroformate ester, is commonly applied to introduce Fmoc group during the formation of Fmoc carbamate. Fmoc-based dipeptides are widely explored as a potential anticancer drug. Fmoc protection also serves as a crucial method in solid phase peptide synthesis because it could be removed by piperidine without disturbing the linker between the peptide and the resin. In addition, due to the fluorescent property of Fmoc group, it could react with certain UV-undetectable compounds to form Fmoc derivatives which are feasible for HPLC analysis. [1]
In vitro: Among thirty studied Fmoc-based dipeptides, there were nine compounds intensively against tumor cell growth in human cancer cell lines including HepG2, Hep3B, MCF-7, MDA-MB-231, A549 and Ca9-22. The most active Fmoc-based dipeptide exhibited the highest sensitivity in Ca9-22 cell lines with an IC50 of 0.4 μM, which was 3-fold more potent than doxorubicin. Moreover, this compound had synergistic effect to enhance the antitumor activity of doxorubicin. [1]
In vivo: Peptide derived from Fmoc solid-phase synthesis was reported to have antiestrogenic and anticancer activities. Specifically, intraperitoneal administration of 0.5 μg such peptide had shown to prevent carcinogen-induced mammary cancer in rats and suppress the growth of ER+ human breast cancer xenografts in mice. [2]
Clinical trial: So far, no clinical trial has been conducted.
References:
[1] Yena CT, Wua CC, Leed JC, Chena SL, Morris-Natschkec SL, Hsiehb PW, Wua YC. Cytotoxic N-(fluorenyl-9-methoxycarbonyl) (Fmoc)-dipeptides: Structure–activity relationships and synergistic studies. Eur J Med Chem. 2010 Jun; 45(6): 2494-502.
[2] Joseph LC, Bennett JA, Kirschner KN, Shields GC, Hughes J, Lostritto N, Jacobsona H, Andersen TT. Antiestrogenic and anticancer activities of peptides derived from the active site of alpha-fetoprotein. J Pept Sci. 2009 Feb; 15: 319–25.
| Cell experiment [1]: | |
|
Cell lines |
Ca9-22 cells |
|
Preparation method |
This compound is soluble in water or 1% acetic acid. General tips for obtaining a higher concentration: Please warm the tube at 37 °C for 10 minutes and/or shake it in the ultrasonic bath for a while. Stock solution can be stored below -20 °C for several months. |
|
Reaction Conditions |
0.4 μM |
|
Applications |
Fmoc-based dipeptide significantly inhibited Ca9-22 cells, with an IC50 value of 0.4 μM. Moreover, this compound had synergistic effect to enhance the antitumor activity of Doxorubicin. |
| Animal experiment [2]: | |
|
Animal models |
Rats with carcinogen-induced mammary cancer and mice bearing ER+ human breast cancer xenografts |
|
Dosage form |
0.5 μg/mouse; i.p. |
|
Applications |
Peptide derived from Fmoc solid-phase synthesis prevented carcinogen-induced mammary cancer in rats and suppressed the growth of ER+ human breast cancer xenografts in mice. |
|
Other notes |
Please test the solubility of all compounds indoor, and the actual solubility may slightly differ with the theoretical value. This is caused by an experimental system error and it is normal. |
|
References: [1]. Yena CT, Wua CC, Leed JC, Chena SL, Morris-Natschkec SL, Hsiehb PW, Wua YC. Cytotoxic N-(fluorenyl-9-methoxycarbonyl) (Fmoc)-dipeptides: Structure–activity relationships and synergistic studies. Eur J Med Chem. 2010 Jun; 45(6): 2494-502. [2]. Joseph LC, Bennett JA, Kirschner KN, Shields GC, Hughes J, Lostritto N, Jacobsona H, Andersen TT. Antiestrogenic and anticancer activities of peptides derived from the active site of alpha-fetoprotein. J Pept Sci. 2009 Feb; 15: 319-25. |
|
| Cas No. | 28920-43-6 | SDF | |
| Chemical Name | 9H-fluoren-9-ylmethyl carbonochloridate | ||
| Canonical SMILES | C1=CC=C2C(=C1)C(C3=CC=CC=C32)COC(=O)Cl | ||
| Formula | C15H11ClO2 | M.Wt | 258.7 |
| Solubility | ≥ 25.9mg/mL in DMSO, ≥ 24.32 mg/mL in EtOH with ultrasonic | Storage | Desiccate at -20°C |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 3.8655 mL | 19.3274 mL | 38.6548 mL |
| 5 mM | 0.7731 mL | 3.8655 mL | 7.731 mL |
| 10 mM | 0.3865 mL | 1.9327 mL | 3.8655 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 30 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *